

20. (New) An isolated polypeptide comprising an amino acid sequence of SEQ ID NO:809.

21. (New) An isolated polypeptide comprising an amino acid sequence having at least 90% identity to an amino acid sequence of SEQ ID NO:809.

22. (New) An isolated polypeptide comprising at least ten consecutive amino acid residues of the amino acid sequence of SEQ ID NO:809.

23. (New) The polypeptide of claim 21 or 22, wherein the polypeptide binds an antibody specific for a polypeptide with an amino acid sequence of SEQ ID NO:809.

24. (New) An isolated polypeptide comprising an immunogenic portion of the amino acid sequence of SEQ ID NO:809.


25. (New) The isolated polypeptide of claim 24, wherein the immunogenic portion consists of contiguous amino acid residues of SEQ ID NO:809 selected from the group consisting of: 16-35, 21-35, 21-40, 26-45, 31-50, 71-90, 86-105, 91-110, 96-115, 101-120, 106-125, 111-130, 116-135, 131-150, and 141-160.

REMARKS

In response to the Restriction Requirement dated September 18, 2002. Applicants have elected claim 2 and the species of SEQ ID NO:809 (L552S). By this amendment, claim 2 has been cancelled, and new claims 20-25 have been added to more specifically describe one aspect of the invention. Applicants submit that support for the new claims is provided throughout the specification as originally filed and that none of the amendments constitute new matter. Specific support for fragments of at least ten consecutive amino acid residues is provided on page 77, lines 5-6, and support for immunogenic portions is provided on page 75, lines 24-25. In addition, support for the specific immunogenic fragments of claim 25 is provided in Examples 18, 25, and 27, which describe the identification of these fragments as epitopes recognized by

antibodies or T cell lines specific for L552S (SEQ ID NO:809). This amendment is not to be construed as acquiescence to any rejection and is made without prejudice to prosecution of any subject matter modified by amendment in a related divisional, continuation, or continuation-in-part application. Favorable consideration and allowance of the elected claims is respectfully requested.

Respectfully submitted,
Robert A. Henderson et al.
Seed Intellectual Property Law Group PLLC


Carol D. Lantry, Ph.D.
Registration No. 51,909

CDL:sd

Enclosure:
Postcard

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

D:\NrPortb\Manage\SandID\322087_1.DOC